New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Prove to Acquire Mobile Behavioral Biometrics Company UnifyID to Accelerate Dynamic Multi-Factor Authentication
-
Prove to Acquire Mobile Behavioral Biometrics Company UnifyID to Accelerate Dynamic Multi-Factor Authentication
-
Form 4 Eargo, Inc. For: May 24 Filed by: New Enterprise Associates 15, L.P.
-
Stride Health's Enrollment Platform powers CMS "Gig Workers' Week of Action" with DoorDash, Postmates, Uber, Wonolo and more
-
Woebot Health Receives FDA Breakthrough Device Designation for Postpartum Depression Treatment
-
Topia Launches New Features To Give Businesses the Visibility, Agility & Compliance They Need to Navigate Post-Pandemic World of Work
-
Form 4 Coursera, Inc. For: May 19 Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Spokn Brings Podcasting to Work with Funding from NEA, Y Combinator
-
3D printer Formlabs doubles valuation after SoftBank fund-led investment round
-
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
-
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
-
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
-
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
-
Large-Scale Study Finds Mental Health App Forms Bond With Users, Marking Key Evolution in Digital Therapeutics
-
Industry Innovator Strive Health Selects Colorado for Headquarters Expansion
-
Aetion Closes $110M Series C Funding Round Led by Warburg Pincus
-
Vori Health Announces $45MM Series A Led By NEA
-
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
Timescale Raises $40M Series B as Cloud Adoption of Its Database Accelerates
-
AIRINC and Topia Establish Strategic Partnership to Deliver Global Talent Mobility Solutions
-
Goody Launches Goody+ To Allow Individuals and Corporations To Make Mobile Gifting More Personal and as Fun and Easy as Sending a Text
-
Affinia Therapeutics Closes $110 Million Series B Financing
-
CIT GAP Funds Invests in Advanced Aircraft Company to Increase Productivity Among UAS Operators
-
Topia Selected by Groupe SEB to Help Take Global Talent Mobility to the Next Level
-
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
-
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
-
Pfizer (PFE) to Acquire Privately-Held Amplyx Pharmaceuticals
-
Pfizer Acquires Amplyx Pharmaceuticals
-
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
-
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
-
Form SC 13D Reneo Pharmaceuticals, Filed by: New Enterprise Associates 15, L.P.
-
Blu Digital Group Secures Additional Investment to Extend Over-subscribed Series "A" Round
-
FemTech Leader Willow ® Adds Diverse Set Of Investors In Extended Series C Round
-
Lumos Pharma (LUMO) Announces Retirement of Carl Langren and Names Lori Lawley CFO in Planned Succession
-
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
-
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
-
4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
-
4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
-
Code Biotherapeutics Launches with $10 Million in Seed Financing to Develop Therapies for Debilitating Genetic Diseases
-
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
-
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
-
OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
-
Form SC 13D/A GENOCEA BIOSCIENCES, Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A Millendo Therapeutics, Filed by: New Enterprise Associates 15, L.P.
-
Beyond Identity Integration With Auth0 Enables Completely Passwordless Authentication
-
Beyond Identity Integration With Auth0 Enables Completely Passwordless Authentication
-
Strive Health Partners With NextGate to Support Whole-Patient Kidney Care
-
Axiado Secures Initial Closing of $20M Series B Investment
-
ICER to Use Aetion Observational RWE to Update Value Assessment of Treatments for Hereditary Angioedema

